Monrovia, CA -- (SBWIRE) -- 05/01/2012 -- Rade Drmanac, Chief Scientific Officer of Complete Genomics will be giving a featured presentation entitled “Large-scale Accurate Whole Genome Sequencing to Enable Genomic Medicine” at the 2nd Next Generation Sequencing Conference on May 29-31st in Boston, MA.
Whole genome sequencing is a revolutionary technology poised to change the way healthcare is managed. WGS provides a powerful method for identifying all genetic variants involved in diseases and other phenotypes. Yet, it can be challenging for researchers to discriminate causal variant(s) from the millions of other contextually interdependent sequence changes. Even so, as a clinical tool, WGS is providing a new strategy for the prevention, diagnosis and treatment of multitudes of diseases including all cancers.
There are many potential uses for whole human genome data in translational medicine and the clinic, especially as more genomes are sequenced; 30,000 genomes are expected to be sequenced this year. Some clinicians have begun to utilize the power of whole genome data to identify and treat undiagnosed diseases and refractory cancers. Sequencing results from WGS projects will be summarized from real-life disease studies.
Benefits of this talk will include:
- Gaining further understanding of how whole genome sequencing is being use to better understand both germline and somatic mutations involved in disease
- Identifying how genetic information can be used as a strategy for the diagnosis and treatment of diseases and conditions
- Reviewing results from real-life genomic medicine examples
- Preparing to tackle some of the obstacles faced with using whole genome sequencing as a tool for genomic medicine
Radoje Drmanac, Ph.D., is co-founder of Complete Genomics and has served as its Chief Scientific Officer since July 2005. He is one of the founders of human genomics and worked in this field for over 25 years. In 2001, Dr. Drmanac co-founded Callida Genomics, Inc., a genomic technology company, and served as Callida’s Chief Scientific Officer from 2001 to 2004 and has served as its President since 2004. In 1994, Dr. Drmanac co-founded Hyseq, Inc., a DNA array and gene discovery company that became Hyseq Pharmaceuticals, Inc. and later merged with Variagenics, Inc. to become Nuvelo, Inc. Rade served as its Senior Vice President of Research from 1994 to 1998 and as its Chief Scientific Officer from 1998 to 2001. Prior to that, Dr. Drmanac served as a group leader at Argonne National Laboratory. Dr. Drmanac received a B.S., M.S. and Ph.D. (1988) in Molecular Biology from the University of Belgrade, Serbia.
For more information, please visit 2nd Next Generation Sequencing Conference or http://www.gtcbio.com